

## Sex and gender in lung health and disease: more than just Xs and Ys

## Jason Weatherald <sup>1,2</sup>, Renata L. Riha <sup>3,4</sup> and Marc Humbert <sup>5,6,7</sup>

<sup>1</sup>Dept of Medicine, Division of Respirology, University of Calgary, Calgary, AB, Canada. <sup>2</sup>Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada. <sup>3</sup>Dept of Sleep Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK. <sup>4</sup>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. <sup>5</sup>Faculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France. <sup>6</sup>INSERM UMR\_S 999 (Pulmonary Hypertension: Pathophysiology and Novel Therapies), Hôpital Marie Lannelongue, Le Plessis-Robinson, France. <sup>7</sup>Dept of Respiratory and Intensive Care Medicine, French Pulmonary Hypertension Reference Center, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France.

Corresponding author: Jason Weatherald (Jason.Weatherald@ahs.ca)



expected outcomes, to the other sex [9]. This raises but one issue related to the often flawed methods implemented in treatment trials and the universality of their results; something that is finally being



recognised by the scientific community at large. We hope that you enjoy this series and that it makes you consider these issues in your day-to-day care, as well as in any future research you may be involved with.

Provenance: Commissioned article, peer reviewed.

Conflict of interest: J. Weatherald reports grants or contracts from Janssen and Actelion, consulting fees from Janssen and Actelion, payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Janssen, support for attending meetings and/or travel from Janssen, and participation on a Data Safety Monitoring Board or Advisory Board for Janssen and Actelion, all outside the submitted work; and being an unpaid committee member for the Pulmonary Hypertension Association of Canada. R.L. Riha reports receiving consulting fees and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Jazz Pharmaceuticals, outside the submitted work. M. Humbert has nothing to disclose.

## References

- 1 Canadian Institutes of Health Research. How to integrate sex and gender into research. https://cihr-irsc.gc.ca/ e/50836.html Date last accessed: 28 September 2021. Date last updated: 21 August 2019.
- 2 LoMauro A, Aliverti A. Sex and gender in respiratory physiology. Eur Respir Rev 2021; 30: 210038.
- 3 Dominelli PB, Molgat-Seon Y. Sex, gender and the pulmonary physiology of exercise. Eur Respir Rev 2021; in press [https://doi.org/10.1183/16000617.0074-2021].
- 4 Somayaji R, Chalmers JD. Just breathe: a review of sex and gender in chronic lung disease. *Eur Respir Rev* 2021; in press [https://doi.org/10.1183/16000617.0111-2021].
- 5 Chowdhury NU, Guntur VP, Newcomb DC, et al. Sex and gender in asthma. Eur Respir Rev 2021; in press [https://doi.org/10.1183/16000617.0067-2021].
- 6 Kawano-Dourado L, Glassberg MK, Assayag D, *et al.* Sex and gender in interstitial lung diseases. *Eur Respir Rev* 2021; in press [https://doi.org/10.1183/16000617.0105-2021].
- 7 Cheron C, McBride SA, Antigny F, *et al.* Sex and gender in pulmonary arterial hypertension. *Eur Respir Rev* 2021; 30: 200330.
- 8 Ragavan M, Patel MI. The evolving landscape of sex-based differences in lung cancer: a distinct disease in women. *Eur Respir Rev* 2021; in press [https://doi.org/10.1183/16000617.0100-2021].
- 9 Glezerman M. Gender Medicine: The Groundbreaking New Science of Gender- and Sex-Related Diagnosis and Treatment. London, Overlook Books, 2016.